Petr Ananin

Dr. Petr Ananin

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMAnastasiia Milovanova
Anastasiia Milovanova
PAPetr Ananin
Petr Ananin
TVTatiana Vashurina
Tatiana Vashurina
OZOlga Zrobok
Olga Zrobok
SDSvetlana Dmitrienko
Svetlana Dmitrienko
TATsygin Alexey
Tsygin Alexey
Schimke immuno-osseous dysplasia (SIOD) is a hereditary autosomal-recessive multi-system disorder with early mortality. It has variable clinical presentations, mainly characterised by disproportional short stature, steroid-resistant nephrotic syndrome, spondyloepiphyseal dysplasia, and T-cell immunodeficiency. In the majority of cases, SIOD is caused by pathogenic sequence variants (PSVs) in the SMARCAL1 gene that encodes protein involved in chromatin remodelling. SIOD is an ultra-rare condition, with an incidence of ~1 per 1–3 million live births; data on its genetic and clinical features are scarce. We conducted a retrospective study of 21 paediatric patients with SIOD diagnosed in our centre during the years 2003–2023. The most common extra-renal clinical features were short stature, osseous dysplasia, multiple stigmas, and leukopenia. Proteinuria of varying severity was observed in 16 cases. The five-year overall survival rate (OS) was 89% (95% CI 77–100%), and the ten-year OS was 10%. Next-generation sequencing (NGS) revealed the following PSVs in SMARCAL1 in 19 patients: c.355_500del, c.2542G>T, c.2290C>T, c.2562del, c.2533_2534del, c.1582A>C, c.1933C>T, c.1010T>C, c.1736C>T, c.2070dup, c.2551A>T, c.2149_2150dup, c.939delC, and c.1451T>A; the most common was c.2542G>T, resulting in premature translation termination (p.E848*), and it was found in 14 patients either in a homozygous (four patients) or compound-heterozygous (10 patients) state. According to microsatellite analysis, it is a “founder mutation” in Russia.

10 October 2018 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
KSKirill Savostyanov
Kirill Savostyanov
NMN.N. Mazanova
N.N. Mazanova
APAleksander Pushkov
Aleksander Pushkov
PAPetr Ananin
Petr Ananin
ASA.V. Sukhozhenko
A.V. Sukhozhenko
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.

30 October 2024 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
РНРасита Александровна Николаева
Расита Александровна Николаева
VMValentina V. Maltseva
Valentina V. Maltseva
PAPetr Ananin
Petr Ananin
AMAnastasiia Milovanova
Anastasiia Milovanova
ТВТатьяна Валерьевна Вашурина
Татьяна Валерьевна Вашурина
TATsygin Alexey
Tsygin Alexey
Introduction. Nephrocalcinosis (NC) is defined as the deposition of calcium oxalate or calcium phosphate in the intratubular lumen and/or kidney interstitium. Recent studies have reported that NC might be a specific sign of hereditary kidney diseases with various phenotypic manifestations. The rate of genetic mutation as a rule was higher in children with earlier onset and positive family history. Purpose. To study the causes, characterize the genotype and phenotype in Russian children with NC. Materials and methods. A single-center retrospective-prospective cohort study included 91 patient under the age of 18 years, 57 (62.6%) boys and 34 (37.4%) girls with bilateral NC. We analyzed the phenotype and kidney function in NC children classified into 3 groups according to etiology: 1) primary tubulopathies; 2) tubulopathies due to metabolic and endocrine disorders; 3) NC, unconfirmed by molecular genetic research. Results. Pathogenic nucleotide variants were identified in 51 (56%) children with a predominance in the genes CLCN5, CYP24A1, AGXT, HPRT1 described in patients with Dent disease (OMIM 300009), primary hyperoxaluria type 1 (OMIM 259900), idiopathic infantile hypercalcemia type 1 (OMIM 143880), Lesh–Nihan syndrome (OMIM 300322) respectively. The median age of detection of NC was 16 years, 4 [3.9; 52.2 months, among which 42 (46.1%) children were under the age of 1 year, 44 (48.4%) aged 1 to 10 years, 5 (5.5%) older than 10 years. Various bone deformities prevailed among the extrarenal manifestations (19 (20.4%)). Over 3 years of follow-up (n = 51) the average GFR changed from 102.5 ± 26.0 ml/min/1.73 m2 to 94.5 ± 21.9 ml/min/1.73 m2 (p = 0.002); over 5 years of follow-up (n = 31) from 104.7 ± 23.9 ml/min/1.73 m2 to 89.6 ± 25.1 ml/min/1.73 m2 (p = 0.002), that was statistically significant in the group of primary tubulopathies (p = 0.030; p = 0.002). At baseline, the average GFR value was lower in NC stages 2 and 3. Conclusion. Conducting a molecular genetic study in NC children, in addition to early diagnosis of diseases with variable renal prognosis and will also help to achieve effectiveness in the timely prescription of pathogenetic and symptomatic therapy.

30 April 2019 in Russian Pediatric Journal
Verified
Journal Article
Open access
PAPetr Ananin
Petr Ananin
OKO. V. Komarova
O. V. Komarova
TVT. V. Vashurina
T. V. Vashurina
OZO. I. Zrobok
O. I. Zrobok
ETE. N. Tsygina
E. N. Tsygina
ATA. N. Tsygin
A. N. Tsygin
Background: Hypophosphatemic rickets is a rare disease, related to renal phosphate waste, which cause bone deformities, and lead to walking abnormalities and to the reduction in the quality of life. Clinical recommendations in different countries vary in medications, recommended doses and surgery approach. The main aim was to analyze phosphate metabolism in children with hypophosphatemic rickets and to evaluate results of conservative and surgical therapy. Methods: We analyzed medical histories of 15 children with hypophosphatemic rickets and investigated phosphate metabolism, including the measurement of serum intact fibroblast growth factor 23 and X-ray bone densitometry. Routine biochemical tests were assessed with our laboratory reference data, the level of iFGF-23 in hypophosphatemic children was compared with the same values in 18 healthy children. Results: We investigated 15 girls with hypophosphatemic rickets, aged of from 3 years 9 months to 18 years 7 months. All children were treated with alphacalcidol and inorganic phosphate (in dose from 16.21 to 103.3 mg/kg, during from 1 to 114 months). Eleven (73%) children had surgical correction of bone deformations, starting at the age of from 3 to 12 years. Ten (91%) of them had the relapse of bone deformations. Two of four children undergone to the correction of bone abnormalities on alphacalcidol and phosphate therapy without surgery. The level of iFGF-23 in children with hypophosphatemic rickets was 73.11 pg/ml, and exceed iFGF-23 in control group (22.92 pg/ml), p =0,009. Conclusion: Early surgical treatment of bone deformations is not indicated in hypophosphatemic rickets because of risk of recurrence, observed in 91% of our patients. There could be spontaneous correction of bone deformation during conservative therapy, when it is started early.

22 September 2025 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
PAPetr Ananin
Petr Ananin
AMAnastasiia Milovanova
Anastasiia Milovanova
KKKirill Kulikov
Kirill Kulikov
ESEkaterina Stolyarevich
Ekaterina Stolyarevich
TATsygin Alexey
Tsygin Alexey

9 August 2024 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
AMAnastasiia Milovanova
Anastasiia Milovanova
PAPetr Ananin
Petr Ananin
TVT.V. Vashurina
T.V. Vashurina
OZO.I. Zrobok
O.I. Zrobok
KSKirill Savostyanov
Kirill Savostyanov
TATsygin Alexey
Tsygin Alexey
Treatment tactics for patients with congenital nephrotic syndrome (CNS) varies from aggressive kinds, such as early nephrectomy, to conservative ones that include diuretic and nutritional support. The purpose of this research was to assess the effectiveness of conservative treatment of children with congenital and infantile nephrotic syndromes. Materials and methods used: a single-center retrospective study of 11 pediatric patients who had been manifested with NS within their first year of life and had required diuretic therapy, was conducted. The effectiveness of conservative therapy was assessed as preservation of the renal function according to glomerular filtration and satisfactory weight/height and height alone parameters’ dynamics that ensure the safety of kidney transplantation. Results: despite the molecular genetic study was conducted in all 250 children with NS, the described 11 have had verified pathogenic variants as follows: in the NPHS1 gene in 5 (45.5%, CI 16.8-76.6%), in the NPHS2 gene in another 5 (45.5%, CI 16.8-76.6%) and a single patient with none of a kind. It was revealed that despite the persistence of pronounced NS laboratory activity, the edema gradually disappeared against the background of conservative therapy, which in its turn had made it possible to refrain from early nephrectomy as well as to begin the renal replacement therapy over the age of 3 (4) y/o. 9 (81.8%, CI 48.2-97.7%) had satisfactory weight and height parameters at the age of 3 y/o. Only a single patient had undergone the early nephrectomy at the age of 4 months old, that was then followed by a successful kidney transplant at the age of 1 year and 4 months old, which, however, did not affect the then positive height prognosis. Conclusion: thus, reasonably selected conservative therapy for CNS can be effective against edematous syndrome and contribute to satisfactory weight/height growth parameters without early nephrectomy and, accordingly, the start of dialysis during the first year of life.